OEP’s growth strategy is focused on four main lines of business.
OEP has been the commercial partner of choice for global pharmaceutical companies for nearly 40 years.
OEP partners with commercial distributors to manufacture and market products in the U.S. and other select markets.
Partners rely on our financial means, technology, and manufacturing capacity to co-develop and launch 505(b)(2)s.
Our state-of-the art facilities are TAA-compliant and USFDA-certified (or will soon receive certification).
With nearly 40 years of local regulatory and sales expertise, and 350+person sales teams in 7 countries, OEP delivers top sales results in our countries of operation.
Over the last 10 years, OEP has developed a growing generics portfolio. We partner with commercial distributors to market our products in the U.S. and other select markets.
Our FDA-certified, PIC/S GMP facility produces medicines at formulations and quantities that can be tailored for each stage, from trial to commercial production. All products are made in Taiwan, a TAA-compliant country. We offer CMO/CDMO as part of a packaged suite, or as a standalone service.
© 2020 OEP Pharma. All right reserved.